Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

An assessment of pH-sensitive cationic lipid nanoparticles for drug delivery

A recent review looks at the molecular design of pH-sensitive cationic lipids and their applications for various tissues and cell types.

7 Dec 2021

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

A new study published on the medRxiv* preprint server analyzed the trajectories of anti-SARS-CoV-2 antibodies in patients from the RituxiVac study were compared to healthy volunteers. In addition, they investigated the immunogenicity of a third vaccine dose in previously non-responding patients.

23 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors - a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions - generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

SARS-CoV-2 reinfection associated with housing instability

Researchers examine the impact of demographic factors and antibody responses following SARS-CoV-2 reinfection.

17 Nov 2021

SARS-CoV-2 protease suppresses host immune response by cleaving NEMO

A recent study conducted by a team of US-based scientists has highlighted a novel function of 3C-like protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The protease has been found to cleave a human immune signaling protein called NF-kB Essential Modulator (NEMO) and disrupt the host immune response.

16 Nov 2021

Study reveals how certain cells drive immunotherapy resistance in ovarian cancer mouse model

Immune checkpoint inhibitors are a type of cancer treatment that help the immune system's T cells recognize and attack tumors. But these immunotherapy drugs aren't effective against all cancers.

12 Nov 2021

Risk of severe COVID-19 is rare among fully vaccinated individuals in England

A team of UK-based scientists has recently estimated the prevalence of vaccine breakthrough infections and severe disease in a large number of individuals fully vaccinated against coronavirus disease 2019 (COVID-19) in England.

10 Nov 2021

Antibody response of COVID-19 patients to SARS-CoV-2 and seasonal coronaviruses

Scientists conducted a cohort study and measured the prevalence and the levels of antibody responses to the nucleocapsid protein of SARS-CoV-2 and four seasonal human coronaviruses.

3 Nov 2021

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.

2 Nov 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.

20 Oct 2021

New atlas of small cell lung cancer reveals rare population of stem-like cells with metastatic properties

Imagine you're about to go on a cross-country trip, stopping at spots along the way to admire local attractions.

15 Oct 2021

Removing high-grade squamous intraepithelial lesions reduces chances of progression to anal cancer

In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.

8 Oct 2021

Novel peptide-drug conjugate enhances the efficacy of immunotherapy in preclinical cancer models

A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint inhibitors in preclinical cancer models, according to results presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021.

7 Oct 2021

Depressed seroconversion in immunocompromised COVID-19 vaccine recipients

Researchers from the University of Singapore have reviewed the data in post-vaccinated immunocompromised patients to examine the effectiveness of these vaccines in these patients.

5 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

Study provides insights on kidney transplant recipients’ immune response to SARS-CoV-2 infection

New research provides insights on the immune responses of kidney transplant recipients following infection with the virus that causes COVID-19. The study, which is published in JASN, may help explain why these individuals face a higher risk of dying from COVID-19 than others in the general population.

4 Oct 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Study to determine the characteristics and outcome of patients hospitalized with COVID-19

The study summarized the clinical presentation and demographic features of patients who were hospitalized with COVID-19.

26 Sep 2021